Thematische Bibliographien / Pertussis vaccines-Testing

Inhaltsverzeichnis

Zeitschriftenartikel
Dissertationen
Bücher
Buchteile

Auswahl der wissenschaftlichen Literatur zum Thema „Pertussis vaccines-Testing“

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 29. Juli 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Pertussis vaccines-Testing" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Pertussis vaccines-Testing"

Robinson, A., and S. G. P. Funnell. "Potency testing of acellular pertussis vaccines." Vaccine 10, no. 3 (1992): 139–41. http://dx.doi.org/10.1016/0264-410x(92)90001-z.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Ausiello, C. M., R. Lande, P. Stefanelli, et al. "T-Cell Immune Response Assessment as a Complement to Serology and Intranasal Protection Assays in Determining the Protective Immunity Induced by Acellular Pertussis Vaccines in Mice." Clinical Diagnostic Laboratory Immunology 10, no. 4 (2003): 637–42. http://dx.doi.org/10.1128/cdli.10.4.637-642.2003.

Der volle Inhalt der Quelle

Annotation:

ABSTRACT The relative value of antibodies and/or T-cell immune responses to Bordetella pertussis antigens in the immunity induced by acellular pertussis (aP) vaccines is still an open issue, probably due to the incomplete knowledge on the mechanisms of protective immunity to pertussis. The relevance of T-cell immune responses in protection from pertussis has been demonstrated in murine and human models of infection; thus, in this study, the ability of different vaccine preparations of three component (pertussis toxin, filamentous hemagglutinin, and pertactin) aP vaccines to induce T-cell respo

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Dimeas, Ilias E., Ourania S. Kotsiou, Polyxeni Salgkami, et al. "Real-Life Insights into Pertussis Diagnosis: High Yield of PCR Testing and Clinical Outcomes—An Emerging Old Enemy or Just a Sign of PCR Times?" Journal of Personalized Medicine 14, no. 12 (2024): 1116. http://dx.doi.org/10.3390/jpm14121116.

Der volle Inhalt der Quelle

Annotation:

Background/Objectives: Pertussis remains a significant public health concern despite effective vaccines due to diagnostic challenges and symptom overlap with other respiratory infections. This study assesses the prevalence of Bordetella pertussis using advanced polymerase chain reaction (PCR) testing and examines the clinical outcomes over a one-month follow-up. Methods: We conducted a cross-sectional study at the University Hospital of Larissa, Greece, from April to June 2024, collecting 532 nasopharyngeal swabs from patients with respiratory symptoms. Diagnostic testing utilized the BioFire®

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Szymkowicz, Lisa, Jeffery Gerard, Benjamin Messham, Wai Tam, and D. James. "Design of a Quantitative LC-MS Method for Residual Toxins Adenylate Cyclase Toxin (ACT), Dermonecrotic Toxin (DNT) and Tracheal Cytotoxin (TCT) in Bordetella pertussis Vaccines." Toxins 13, no. 11 (2021): 763. http://dx.doi.org/10.3390/toxins13110763.

Der volle Inhalt der Quelle

Annotation:

The antigens for acellular pertussis vaccines are made up of protein components that are purified directly from Bordetella pertussis (B. pertussis) bacterial fermentation. As such, there are additional B. pertussis toxins that must be monitored as residuals during process optimization. This paper describes a liquid chromatography mass spectrometry (LC-MS) method for simultaneous analysis of residual protein toxins adenylate cyclase toxin (ACT) and dermonecrotic toxin (DNT), as well as a small molecule glycopeptide, tracheal cytotoxin (TCT) in a Pertussis toxin vaccine antigen. A targeted LC-MS

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Oh, Hokyung, Jeewon Joung, Byoung-Guk Kim, et al. "Improved protocols for histamine sensitization testing of acellular pertussis vaccines." Vaccine 30, no. 50 (2012): 7246–52. http://dx.doi.org/10.1016/j.vaccine.2012.10.005.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Sesardic, D., C. S. Dawes, K. Mclellan, Z. Durrani, S. E. Yost, and M. J. Corbel. "Non-pertussis Components of Combination Vaccines: Problems with Potency Testing." Biologicals 27, no. 2 (1999): 177–81. http://dx.doi.org/10.1006/biol.1999.0205.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Klein, David L. "Multicenter Acellular Pertussis Vaccine Trial: A National Institutes of Health Perspective." Pediatrics 96, no. 3 (1995): 547–48. http://dx.doi.org/10.1542/peds.96.3.547.

Der volle Inhalt der Quelle

Annotation:

The Pertussis Program within the Division of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, is responsible for the development, management, and monitoring of several research and training initiatives in the field of pertussis. As directed by Congress through the National Childhood Injury Act, and with support by the National Vaccine Program Office, the NIAID has a mandate to accelerate scientifically and systematically the development and clinical testing of new candidate acellular pertussis vaccines, wi

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Hoonakker, Marieke Esther. "In Vivo Models and In Vitro Assays for the Assessment of Pertussis Toxin Activity." Toxins 13, no. 8 (2021): 565. http://dx.doi.org/10.3390/toxins13080565.

Der volle Inhalt der Quelle

Annotation:

One of the main virulence factors produced by Bordetella pertussis is pertussis toxin (PTx) which, in its inactivated form, is the major component of all marketed acellular pertussis vaccines. PTx ADP ribosylates Gαi proteins, thereby affecting the inhibition of adenylate cyclases and resulting in the accumulation of cAMP. Apart from this classical model, PTx also activates some receptors and can affect various ADP ribosylation- and adenylate cyclase-independent signalling pathways. Due to its potent ADP-ribosylation properties, PTx has been used in many research areas. Initially the research

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Saso, Anja, Beate Kampmann, and Sophie Roetynck. "Vaccine-Induced Cellular Immunity against Bordetella pertussis: Harnessing Lessons from Animal and Human Studies to Improve Design and Testing of Novel Pertussis Vaccines." Vaccines 9, no. 8 (2021): 877. http://dx.doi.org/10.3390/vaccines9080877.

Der volle Inhalt der Quelle

Annotation:

Pertussis (‘whooping cough’) is a severe respiratory tract infection that primarily affects young children and unimmunised infants. Despite widespread vaccine coverage, it remains one of the least well-controlled vaccine-preventable diseases, with a recent resurgence even in highly vaccinated populations. Although the exact underlying reasons are still not clear, emerging evidence suggests that a key factor is the replacement of the whole-cell (wP) by the acellular pertussis (aP) vaccine, which is less reactogenic but may induce suboptimal and waning immunity. Differences between vaccines are

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Pillsbury, Alexis, Helen E. Quinn, and Peter B. McIntyre. "Australian vaccine preventable disease epidemiological review series: pertussis, 2006–2012." Communicable Diseases Intelligence 38 (September 1, 2014): 179–94. https://doi.org/10.33321/cdi.2014.38.34.

Der volle Inhalt der Quelle

Annotation:

Despite pertussis vaccine being available since the 1940s and immunisation programs using combined diphtheria-tetanus-pertussis vaccine since the mid-1950s, pertussis has been the most commonly notified vaccine preventable disease in Australia over the past 20 years. Pertussis notification and hospitalisation data have been available nationally since 1993, and provide different perspectives for understanding epidemiological trends. This report follows on from a previous review of Australian pertussis epidemiology from 1995–2005 and summarises routinely collected notification, hospitalisation a

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Dissertationen zum Thema "Pertussis vaccines-Testing"

Greig, Alan J. "A cell-based assay for the safety testing of pertussis-containing vaccines." Thesis, University College London (University of London), 2018. http://discovery.ucl.ac.uk/10048192/.

Der volle Inhalt der Quelle

Annotation:

Since the advent of the acellular pertussis vaccine, safety testing has been carried out using the Histamine Sensitisation Assay (HIST assay). This assay is crude in nature and involves large numbers of mice to ensure statistically relevant output. In this work, a permeability assay is described that is a viable alternative to the HIST assay. Human Umbilical Vein Endothelial Cells (HUVECs) in co-culture with peripheral blood mononuclear cells (PBMCs) were used in a permeability assay to distinguish a preparation of DTaP5-IPV-Hib vaccine spiked with pertussis toxin (PTx) from a second control p

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Bücher zum Thema "Pertussis vaccines-Testing"

T, Perkins F., International Association of Biological Standardization., and World Health Organization, eds. Proceedings of the Fourth International Symposium on Pertussis: A joint meeting of the International Association of Biological Standardization and the World Health Organization held at the Executive Board room of the World Health Organization, Geneva, Switzerland 25.-27. Sept. 1984. S. Karger, 1985.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

1925-, Brown Fred, and Istituto Superiore di Sanità, eds. Pertussis vaccine trials: Istituto Superiore di Sanità, Italy, October 30-November 1, 1995. Karger, 1997.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Buchteile zum Thema "Pertussis vaccines-Testing"

Althouse, Benjamin M., and Samuel V. Scarpino. "Contrasting ecological and evolutionary signatures of whooping cough epidemiological dynamics." In Pertussis. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780198811879.003.0013.

Der volle Inhalt der Quelle

Annotation:

The enigmatic global pattern of whooping cough incidence presents a unique set of challenges for controlling the disease and uncovering the mechanisms underlying its epidemiological dynamics. In countries experiencing an increase in cases, five hypotheses have been proposed to explain the resurgence: (1) there has been an increase in Bordetella pertussis reporting rates, (2) waning of protective immunity from vaccination or natural infection over time, (3) evolution of B. pertussis to escape protective immunity, (4) vaccines that fail to induce sterilizing (mucosal) immunity to B. pertussis, a

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!